RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection Jan 11, 2017
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083 Jan 10, 2017
RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management Jan 10, 2017
RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference Jan 7, 2017
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA Jan 6, 2017
Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders Dec 17, 2016
DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083 Dec 15, 2016
Resverlogix Announces Filing of Quarterly Financial Statements and Management’s Discussion & Analysis Dec 14, 2016
Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208) Dec 6, 2016
DelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting Nov 22, 2016
Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies Nov 18, 2016
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2017 Financial Results and Corporate Update Nov 15, 2016
RedHill Biopharma Reports Positive FDA Type B Meeting on RHB-105 for H. pylori Infection Ahead of Confirmatory Phase III Study Nov 11, 2016
DelMar Pharmaceuticals Presents New VAL-083 Data at Two International Scientific Conferences Nov 8, 2016
RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA® and Expected Timing of Top-Line Results Nov 4, 2016
DelMar Pharmaceuticals Presents Overview of VAL-083’s Unique Anticancer Mechanism at the European Association of Neuro-Oncology (EANO) Annual Meeting Oct 18, 2016
